OrbiMed Reduces Adicet Bio Stake to 8.8% After $1.2M Share Sales

summarizeSummary

OrbiMed Advisors, a significant institutional investor, reported selling approximately $1.2 million worth of Adicet Bio shares, reducing its beneficial ownership to 8.8%.

check_boxKey Events

• Significant Stake Reduction

  OrbiMed Advisors LLC and its affiliates have reduced their beneficial ownership in Adicet Bio, Inc. to 8.8% of the outstanding common stock.

• $1.2 Million in Share Sales

  The reduction resulted from the sale of 183,158 shares across several transactions on April 7th and 8th, 2026, and a reported sale on April 9, 2025, with total proceeds of approximately $1.2 million.

• Ongoing Investor Activity

  This filing follows recent Form 144 filings from other parties and occurs in the context of Adicet Bio's recent highly dilutive offering and reverse stock split.

auto_awesomeAnalysis

OrbiMed Advisors LLC and its affiliates, a major institutional investor, have filed an Amendment No. 9 to their Schedule 13D, reporting a reduction in their beneficial ownership of Adicet Bio, Inc. to 8.8% of the outstanding common stock. This decrease follows the sale of 183,158 shares across multiple transactions on April 7th and 8th, 2026, and a historical sale on April 9, 2025, totaling approximately $1.2 million. While institutional investors frequently adjust their holdings, a significant reduction by a major holder can signal a shift in investment sentiment or a need for liquidity. This comes after Adicet Bio's recent highly dilutive offering and reverse stock split, suggesting continued pressure on shareholder value.